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Case Report
Verruca Eradication Following Conversion to Sirolimus in a Renal 
Transplant Recipient after Longstanding Cyclosporine A Treatment
Dong Jin Joo, M.D.1,2, Sung Hoon Kim, M.D.1, Kyu Ha Huh, M.D.1,2 and Yu Seun Kim, M.D.1,2
Department of Surgery1, Research Institute for Transplantation2, Yonsei University Health System, Seoul, Korea
We present the case of a 50-year-old male kidney transplant recipient whose verruca skin warts completely disappeared 
after conversion of immunosuppressive treatment from cyclosporine A to sirolimus. Before conversion, the patient underwent 
three sessions of cryotherapy, but this treatment failed to produce noticeable improvement in wart number or severity. In 
this case of a transplant recipient under CsA-based immunosuppression, change of immunosuppressive treatment to sirolimus 
produced dramatic improvement in the elimination of verruca warts.
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Introduction
Dermatological complications, such as, human papil-
lomavirus (HPV)-induced warts, following transplanta-
tion are common in transplant recipients. In particular, 
warts are often recalcitrant to common treatments, and 
may become giant and painful, and thus, significantly 
impact quality of life(1). Furthermore, as duration of 
exposure to an immunosuppressive agent increases, 
the risks of these complications also increase(2), and 
are further increased by calcineurin inhibitors(3,4). 
Recently, sirolimus was introduced as a immunosup-
pressive, anti-malignancy, and anti-viral agent(5). Here, 
we describe the dramatic disappearance of verruca 
warts after initiating sirolimus in a renal transplant 
recipient.
Case Report
A 50-year-old renal transplant recipient complained 
of increasing numbers of skin warts on his hands and 
feet (Fig. 1A, B). Since kidney transplantation in 1994, 
he had been treated with cyclosporine A (CsA; 
Sansdimun Neoral, Novartis, Basel, Switzerland) and 
prednisolone (Solondo, Yuhan Medica, Cheongwon, 
Korea) for immunosuppression, and in 2002, he also 
started mycophenolic acid therapy (Myfortic, Novartis). 
Throughout this period, the CsA trough levels had 
been maintained at between 80 and 120 ng/mL. His 
renal function was stable, and his baseline creatinine 
level was around 1.5 mg/dL and had been well main-
tained before sirolimus conversion. His estimated glo-
merular filtration rate (eGFR; calculated by modifica-
tion of diet in using the renal disease equation) re-
mained at around 50∼60 mL/min/1.73 m2 since kid-
ney transplantation. He had experienced no acute re-
jection episode but 24-hour urine collection showed 
proteinuria at around 1,000 mg/day. The warts had 
grown slowly for 2 years from 2009, and in 2010, he 
was sent to the Department of Dermatology where he 
was diagnosed to have verruca vulgaris on both hands 
and feet, and underwent three sessions of cryotherapy. 
However, this failed to produce a noticeable improve-
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Fig. 1. Skin lesions before and after sirolimus conversion. The patient complained of severe skin warts on the hands and feet (A, 
B). Four months after conversion from cyclosporine A to sirolimus, the skin lesions dramatically disappeared (C, D).
ment in wart number or severity. Because of this fail-
ure, sirolimus (Rapamune, Pfizer, New York, NY, 
USA) conversion was attempted from June, 2011. 
Sirolimus was loaded at 4 mg on the first day of con-
version and followed by a maintenance dose of 2 
mg/day. After starting sirolimus treatment, CsA was ta-
pered by 25% weekly. The target trough level for siro-
limus was 12∼24 ng/mL. For 1 year after sirolimus 
conversion, no acute rejection episode occurred and 
serum creatinine levels and eGFR remained at accept-
able levels (around 1.5 mg/dL and at 50∼60 mL/min/ 
1.73 m2, respectively). However, 1 month after starting 
sirolimus, the patient developed sirolimus induced in-
terstitial pneumonitis, which was confirmed by bron-
choscopy and chest computed tomography scan. At 
the time of diagnosis, his sirolimus blood levels were 
18∼24 ng/mL. The pneumonitis was relieved by re-
ducing the dose of sirolimus to maintain sirolimus 
trough levels between 5 and 10 ng/mL. Interestingly, 
4 months after starting sirolimus, the skin lesions dra-
matically disappeared (Fig. 1C, D). For 1 year after si-
rolimus conversion, his serum creatinine levels re-
mained stable at around 1.5 mg/dL and serum siroli-
mus concentrations at around 5.0 ng/mL, but micro-
protein in 24-hour urine collection increased up to 
2,500 mg/day.
Discussion
Renal transplant recipients are predisposed to vari-
ous dermatologic lesions, for example, HPV infections 
affect 6∼92% of renal transplant recipients(6). Skin le-
sions can be associated with various skin infections, 
such as, viral, bacterial, or fungal infections, and vi-
ral-induced verruca vulgaris infection is apparently the 
most common skin infection in renal recipients(7).
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In contrast to that observed in the healthy pop-
ulation, HPV-induced warts in transplant recipients 
may be resistant to common treatments, which mainly 
involve physical and/or chemical lesion destruction. 
Many transplant physicians have attempted to reduce 
immunosuppression in these patients but it has been 
considered as an insufficient method, and some case 
reports have mentioned the use of sirolimus for the 
treatment of warts in transplant recipients(8-10). Siroli-
mus is known to have an anti-proliferative effect, but 
little is known of the mechanism involved, and little 
information is available on the effect of sirolimus on 
HPV infections. On the other hand, the inhibition of 
virus replication by mammalian target of rapamycin in-
hibitors was recently investigated(11,12). In our case, 
we cannot exclude the possibility that CsA withdrawal 
contributed to wart regression. However, there was a 
report that sirolimus conversion showed successful re-
sult for the patients who was failed in the reduction 
of immunosuppression(10).
There can be some other treatment modalities. 
Bonatti et al.(13) reported effective response to local 
cidofovir in a series of six transplant recipients with 
HPV-associated skin lesions.
Sirolimus poses the risks of potentially fatal side ef-
fects, such as, pneumonitis, and has side effects that 
include proteinuria, hyperlipidemia, leg edema, and 
oral ulcer(14). Accordingly, close monitoring of siroli-
mus blood levels are required to minimize the risks of 
side effects(15). No definite indications are available 
for sirolimus conversion from a calcineurin inhibitor. 
However, the present case shows that sirolimus con-
version can have a dramatic effect on verruca warts in 
transplant recipients under CsA-based immunosuppre-
ssion.
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